56985-40-1
56985-40-1 结构式
基本信息
9,11-二脱氧基-11Α,9Α-亚甲基环氧前列腺素 F2Α
9,11-二脱氧基-9Α,11Α-亚甲基环氧前列腺素 F2Α溶液
9,11-DIDEOXY-11Α,9Α-EPOXYMETHANOPROSTAGLANDIN F2Α
9,11-Methanoxy-PGH2
9,11-Methanoepoxy PGH2
11α,9α-Epoxymethanoprostaglandin H2
U-46619 - CAS 56985-40-1 - Calbiochem
9,11-DIDEOXY-11ALPHA,9ALPHA-EPOXYMETHANO
4-alpha,5-beta(z),6-alpha(1e,3s*)))-r-(1-alph
9,11-dideoxy-11α,9α-epoxymethanoprostaglandin f2α
9,11-dideoxy-11A,9A-epoxymethano-*prostaglandin F
9,11-DIDEOXY-9ALPHA,11ALPHA-METHANOEPOXY PGF2ALPHA
物理化学性质
安全数据
常见问题列表
U-46619是一种PGH2类似物，可以用作血栓烷A2（TP）受体激动剂，影响人类血管平滑肌的促有丝分裂生长。U 46619是稳定的血栓烷A2模拟物，是H2内过氧化物前列腺素的类似物，用作血管收缩剂和血栓烷受体激动剂。
TXA2
U-46619 (1 nM-10 μM) causes platelets shape change and aggregation in a concentration-dependent manner, and with EC
50
s of 0.58 μM and 0.013 μM for aggregation and shape change, respectively.
U-46619 (10 nM-10 μM) increases internal Ca
2+
concentration ([Ca
2+
]i) and activates phosphoinositide (PI) hydrolysis in a concentration-dependent manner with a similar concentration-dependency.
U-46619 (3 nM-10 μM) also activates GTPase concentration-dependently in the membranes derived from platelets.
U-46619 improves the differentiation efficiency of human induced pluripotent stem cells into endothelial cells by activating both p38MAPK and ERK1/2 signaling pathways.
U-46619 (5 μg/kg; i.v.) increases blood pressure in male spontaneously hypertensive rats (SHR).
| Animal Model: | 12-15 weeks-old male and female SHR |
| Dosage: | 5 μg/kg |
| Administration: | Intravenous injection |
| Result: | Induceed a significant increase of MABP after 1 min in male SHR. |